Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.69 |
| ▸ | HPGD | P15428 | 4/20 | 0.69 |
| ▸ | MAOA | P21397 | 2/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.69 |
| ▸ | DRD1 | P21728 | 1/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.69 |
| ▸ | HTR2B | P41595 | 1/20 | 0.69 |
| ▸ | CCR2 | P41597 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1-Naphthylisothiocyanate SCHEMBL29354904 | 0.82 | ALDH1A1 (1.00) | ALDH1A1CYP1A2HSD17B10HPGDMAOA | |
| 1-Naphthylisothiocyanate SCHEMBL419795 | 0.82 | ALDH1A1 (1.00) | ALDH1A1CYP1A2HSD17B10HPGDMAOA | |
| Acridine SCHEMBL27860146 | 0.81 | ALDH1A1 (0.59) | ALDH1A1CYP1A2HSD17B10HPGDMAOA | |
| SCHEMBL3714186 | 0.81 | CYP3A4 (0.48) | ALDH1A1CYP1A2HSD17B10HPGDMAOA | |
| SCHEMBL3901680 | 0.80 | ALDH1A1 (0.49) | ALDH1A1CYP1A2HSD17B10HPGDMAOA | |
| 1-Naphthylisothiocyanate SCHEMBL27570428 | 0.80 | ALDH1A1 (0.96) | ALDH1A1CYP1A2HSD17B10HPGDMAOA | |
| 1-Naphthylisothiocyanate SCHEMBL27487887 | 0.80 | ALDH1A1 (0.96) | ALDH1A1CYP1A2HSD17B10HPGDMAOA | |
| SCHEMBL3904604 | 0.79 | ALDH1A1 (0.55) | ALDH1A1CYP1A2HSD17B10HPGDMAOA | |
| SCHEMBL37656 | 0.79 | ALDH1A1 (0.61) | ALDH1A1CYP1A2HSD17B10HPGDMAOA | |
| SCHEMBL13138480 | 0.78 | ALDH1A1 (0.42) | ALDH1A1CYP1A2HSD17B10HPGDMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590479-B1 | NUCLEIC ACID AMPLIFICATION | GE HEALTHCARE BIO SCIENCES (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20100212548-A1 | Immersion Liquid And Method For Preparing An Organic Compound For An Immersion Liquid | CARL ZEISS AG (DE) | 2010-08-26 | — | — | US | disclosed |
| US-20100212548-A1 | Immersion Liquid And Method For Preparing An Organic Compound For An Immersion Liquid | CARL ZEISS AG (DE) | 2010-08-26 | — | — | US | disclosed |
| EP-1421213-B1 | LABELED NUCLEOSIDE POLYPHOSPHATES | GE HEALTHCARE BIO SCIENCES (US) | 2010-02-17 | — | — | EP | disclosed |
| EP-1592779-A4 | TERMINAL-PHOSPHATE-LABELED NUCLEOTIDES WITH NEW LINKERS | GE HEALTHCARE BIO SCIENCES (US) | 2007-12-12 | — | — | EP | disclosed |
| US-7125671-B2 | Nucleic acid amplification with terminal-phosphate labeled nucleotides | GE HEALTHCARE BIO-SCIENCES CORP. (US) | 2006-10-24 | — | — | US | disclosed |
| US-7041812-B2 | Labeled nucleoside polyphosphates | AMERSHAM BIOSCIENCES CORP (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1590479-A4 | NUCLEIC ACID AMPLIFICATION | AMERSHAM BIOSCIENCES CORP (US) | 2006-04-05 | — | — | EP | disclosed |
| EP-1592779-A2 | TERMINAL-PHOSPHATE-LABELED NUCLEOTIDES WITH NEW LINKERS | Amersham Biosciences Corp. (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1590479-A1 | NUCLEIC ACID AMPLIFICATION | Amersham Biosciences Corp. (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004072238-A2 | TERMINAL-PHOSPHATE-LABELED NUCLEOTIDES WITH NEW LINKERS | AMERSHAM BIOSCIENCES CORP (US) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004072304-A1 | NUCLEIC ACID AMPLIFICATION | AMERSHAM BIOSCIENCES CORP (US) | 2004-08-26 | — | — | WO | disclosed |
| US-4966856-A | QUANTITATIVE ANALYSIS OF FLUID SAMPLES | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1990-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100212548-A1 | Immersion Liquid And Method For Preparing An Organic Compound For An Immersion Liquid | F12, NR1H3, FLI1 | ALDH1A1 2122/4885CYP1A2 545/4885HSD17B10 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.